Exobiosphere Partners with Voyager Technologies on ISS Mission

On Wednesday 13 May 2026, Luxembourg-based space biotech company Exobiosphere and Voyager Technologies announced a mission management contract on the International Space Station (ISS) that marks a step toward making automated biological research in microgravity commercially accessible to researchers, agencies, pharmaceutical and biotech partners.

Under the contract, Voyager Technologies Europe will serve as mission integrator for the Orbital High-Throughput Screener (OHTS), Exobiosphere’s miniaturised platform aboard the ISS, with target launch date of March 2027.

Voyager will also provide project management support, including safety and verification to NASA Safety Review standards, integration aboard the ISS and coordination of on-orbit operations for the permanently installed OTHS payload.

“Our agency, research and biotech partners have been telling us the same thing: they need high-throughput automated systems, increased access and a higher cadence. Permanent hardware on station means we can serve partners continuously and start building the operational track record that opens the door to pharma and biotech at scale,” said Kyle Acierno, CEO of Exobiosphere.

“Our mission management services exist to build a clear path for innovative ideas to become a reality in space,” said Matt Magaña, President of Space, Defence and National Security, Voyager. “Facilitating this access to the ISS is critical to improving life here on Earth and irrespective of platform, we have a proven path to do that.”

Built for repeat use, the OHTS architecture is modular: samples and consumable elements can be exchanged between campaigns, giving pharmaceutical and biotech clients a continuous pipeline of experiments without requiring a new hardware deployment each time. Follow-on contracts are expected.

“OHTS is the first payload of its kind, capable of running over 2,000 simultaneous drug screening samples in a single mission, with integrated brightfield and fluorescence microscopy, luminescence reading and fully autonomous media and reagent exchange,” said Olivia Borgue, Co-Founder and Director of Engineering, Exobiosphere. “Having Voyager’s expertise in ISS integration and mission management by our side means we can focus entirely on advancing the science and delivering real value to our clients.”

Exobiosphere said the contract reinforces Voyager’s track record of facilitating access to low-Earth orbit and advances its mission to improve life on Earth through microgravity research.

“Voyager Technologies Europe is committed to supporting Europe’s growing ambitions in Low Earth Orbit by working with International Space Station capabilities today and preparing for the next phase of commercial space stations with Starlab,” said Mattia Pianorsi, Managing Director, Voyager Technologies Europe. “Our presence in Europe allows us to work closely with regional partners and institutions, turning advanced concepts into operational missions.”